All News
Filter News
Found 808,916 articles
-
CLS Americas Announces the National Institutes of Health Clinical Center Placed its 1st Order of the TRANBERG™ Thermal Therapy System for its Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer
6/1/2023
Clinical Laserthermia Systems Americas, Inc., a leading provider of office-based, focal laser ablation systems for urologists, announced it has received the first order of its TRANBERG™ Thermal Therapy System and accessories from the National Institutes of Health Clinical Center.
-
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
6/1/2023
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration.
-
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
6/1/2023
AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
-
Cognoa Announces Leadership Expansion with Strategic Hires
6/1/2023
Cognoa announced the expansion of its leadership team supporting the commercialization of Canvas Dx, the first and only FDA authorized diagnostic that gives diverse providers the ability to diagnose or rule out autism in children ages 1.5 to 6 years at risk of developmental delay.
-
Medtronic names Ken Washington new Chief Technology and Innovation Officer
6/1/2023
Medtronic plc announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer.
-
invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines
6/1/2023
invoX Pharma Limited announced that it has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.
-
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
6/1/2023
Alkermes plc announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc, the new independent public company to be established upon the planned separation of Alkermes' oncology business.
-
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer
6/1/2023
Nykode Therapeutics ASA announced that it has expanded the clinical collaboration and supply agreement with Roche to cover evaluation of VB10.16, Nykode’s wholly owned off-the-shelf therapeutic cancer vaccine candidate, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first line treatment.
-
Cassava Sciences to Present at the 2023 Jefferies Global Healthcare Conference
6/1/2023
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.
-
Caris Life Sciences and ConcertAI Expand Partnership to Create First-in-Class, Prospectively Matched Clinico-Genomic Research Platform
6/1/2023
Caris Life Sciences® and ConcertAI announced an expanded translational sciences and clinical development solutions partnership.
-
DiviTum(R) TKa Results to be Presented at ASCO
6/1/2023
Biovica, active in cancer diagnostics, announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world's largest cancer conference, the annual ASCO meeting, on Sunday, June 4.
-
MaxCyte to Participate in Upcoming June 2023 Investor Conferences
6/1/2023
MaxCyte, Inc. announced Company management will participate at the following investor conferences:
-
Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections
6/1/2023
Pneumagen announced that it has secured £8 million in financing from existing and new investors to support the continued Phase 2 development of Neumifil in Chronic Obstructive Pulmonary Disease patients suffering from virus induced exacerbations.
-
Philips and Masimo introduce new, advanced monitoring capabilities to Philips high acuity patient monitors
6/1/2023
Royal Philips announced FDA clearance allowing the activation of SedLine® Brain Function Monitoring, Regional Oximetry, and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850.
-
Amarin to Present at Two Upcoming June 2023 Investor Conferences
6/1/2023
Amarin Corporation plc announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences.
-
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
6/1/2023
Antengene Corporation Limited announced that XPOVIO® in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of adult patients with R/R MM who have received at least one prior therapy.
-
Ondine Biomedical Appoints Senior Pharma Executive Dr. Simon Sinclair as Chief Medical Officer
6/1/2023
Canadian life sciences company Ondine Biomedical has appointed Dr. Simon Sinclair as Chief Medical Officer, as the Company prepares to start the US Phase 3 trial of its nasal photodisinfection technology.
-
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
6/1/2023
Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR² Therapeutics Inc.
-
CureScience™ Institute Publishes A Review Article on Neoantigens
6/1/2023
CureScience™ Institute is pleased to announce the publication of "Designing neoantigen cancer vaccines, trials, and outcomes" by Biswas, N., Chakrabarti, S., Padul, V., Jones, L. D., & Ashili, S.
-
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
6/1/2023
Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries.